Compugen (Compugen) Beneish M-Score

: 40.01 (As of Today)

View and export this data going back to 2000. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 40.01 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Compugen's Beneish M-Score or its related term are showing as below:

CGEN' s Beneish M-Score Range Over the Past 10 Years
Min: -7.04 Med: -0.06 Max: 44.08
Current: 40.01

During the past 13 years, the highest Beneish M-Score of Compugen was 44.08. The lowest was -7.04. And the median was -0.06.

Compugen Beneish M-Score Historical Data

The historical data trend for Compugen's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compugen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beneish M-Score

-1.93

-1.77

40.01

Compugen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Beneish M-Score																-1.77	-	-	-	40.01

Competitive Comparison

For the Biotechnology subindustry, Compugen's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Compugen Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, Compugen's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Compugen's Beneish M-Score falls into.

Compugen Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Compugen for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 43.3584

0.528 * 0.9254

0.404 * 0.6963

0.892 * 4.4612

0.115 * 0.7966

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 0.1987

4.679 * 0.141214

0.327 * 1.583

40.00

This Year (Dec23) TTM:

Last Year (Dec22) TTM:

Total Receivables was $61.32 Mil.
Revenue was $33.46 Mil.
Gross Profit was $31.46 Mil.
Total Current Assets was $114.58 Mil.
Total Assets was $121.33 Mil.
Property, Plant and Equipment(Net PPE) was $2.55 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.48 Mil.
Selling, General, & Admin. Expense(SGA) was $9.98 Mil.
Total Current Liabilities was $26.27 Mil.
Long-Term Debt & Capital Lease Obligation was $0.72 Mil.
Net Income was $-18.75 Mil.
Gross Profit was $-0.00 Mil.
Cash Flow from Operations was $-35.89 Mil.

Total Receivables was $0.32 Mil.
Revenue was $7.50 Mil.
Gross Profit was $6.53 Mil.
Total Current Assets was $86.13 Mil.
Total Assets was $94.18 Mil.
Property, Plant and Equipment(Net PPE) was $3.36 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.48 Mil.
Selling, General, & Admin. Expense(SGA) was $11.25 Mil.
Total Current Liabilities was $11.92 Mil.
Long-Term Debt & Capital Lease Obligation was $1.31 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(61.318 / 33.459)	/	(0.317 / 7.5)
	=	1.832631	/	0.042267
	=	43.3584

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(6.525 / 7.5)	/	(31.455 / 33.459)
	=	0.87	/	0.940106
	=	0.9254

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (114.579 + 2.545) / 121.334)	/	(1 - (86.125 + 3.358) / 94.176)
	=	0.034698	/	0.049832
	=	0.6963

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	33.459	/	7.5
	=	4.4612

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.482 / (0.482 + 3.358))	/	(0.476 / (0.476 + 2.545))
	=	0.125521	/	0.157564
	=	0.7966

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(9.975 / 33.459)	/	(11.251 / 7.5)
	=	0.298126	/	1.500133
	=	0.1987

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0.719 + 26.266) / 121.334)	/	((1.312 + 11.919) / 94.176)
	=	0.222403	/	0.140492
	=	1.583

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-18.754 - -0.002	-	-35.886)	/	121.334
	=	0.141214

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Compugen has a M-score of 40.00 signals that the company is likely to be a manipulator.

Compugen Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Compugen's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Compugen (Compugen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compugen Ltd (NAS:CGEN) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

CGEN:Israel

Address

26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849

Website

https://www.cgen.com

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.